These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12957644)

  • 21. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formulation and evaluation of insulin dry powder for inhalation.
    Mahesh Kumar T; Misra A
    Drug Dev Ind Pharm; 2006 Jul; 32(6):677-86. PubMed ID: 16885123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):350-3. PubMed ID: 14993760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ; Chan LW; Heng PWS
    Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Inagaki Y; Todo H; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):938-42. PubMed ID: 15304985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.
    Lucas P; Anderson K; Staniforth JN
    Pharm Res; 1998 Apr; 15(4):562-9. PubMed ID: 9587952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS)].
    Iida K; Leuenberger H; Fueg LM; Müller-Walz R; Okamoto H; Danjo K
    Yakugaku Zasshi; 2000 Jan; 120(1):113-9. PubMed ID: 10655787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lactose characteristics and the generation of the aerosol.
    Pilcer G; Wauthoz N; Amighi K
    Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations.
    Price R; Young PM; Edge S; Staniforth JN
    Int J Pharm; 2002 Oct; 246(1-2):47-59. PubMed ID: 12270608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenbergerb H
    Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1455-7. PubMed ID: 14646332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dry powder inhaler device influence on carrier particle performance.
    Donovan MJ; Kim SH; Raman V; Smyth HD
    J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation.
    Traini D; Young PM; Jones M; Edge S; Price R
    Eur J Pharm Sci; 2006 Feb; 27(2-3):243-51. PubMed ID: 16330191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
    Donovan MJ; Smyth HD
    Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
    Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
    Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS; Lau R
    Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Rational Design Space for Optimizing Mixing Conditions for Formation of Adhesive Mixtures for Dry-Powder Inhaler Formulations.
    Sarkar S; Minatovicz B; Thalberg K; Chaudhuri B
    J Pharm Sci; 2017 Jan; 106(1):129-139. PubMed ID: 27546350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationships between surface coverage ratio and powder mechanics of binary adhesive mixtures for dry powder inhalers.
    Rudén J; Frenning G; Bramer T; Thalberg K; Alderborn G
    Int J Pharm; 2018 Apr; 541(1-2):143-156. PubMed ID: 29454905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modification of electrostatic charge on inhaled carrier lactose particles by addition of fine particles.
    Bennett FS; Carter PA; Rowley G; Dandiker Y
    Drug Dev Ind Pharm; 1999 Jan; 25(1):99-103. PubMed ID: 10028425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):72-80. PubMed ID: 16442248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.